首页> 美国政府科技报告 >STAT3 in Neurofibroma Tumorigenesis and Therapy.
【24h】

STAT3 in Neurofibroma Tumorigenesis and Therapy.

机译:sTaT3在神经纤维瘤肿瘤发生和治疗中。

获取原文

摘要

Neurofibromatosis type 1 patients develop benign neurofibromas and malignant peripheral nerve sheath tumors (MPNSTs). Growth factor receptors, particularly EGFR, have been implicated in neurofibroma formation and progression, but their precise roles and relevant signaling pathways remain unknown. We found that EGFR modifies neurofibroma-initiating cell number and promotes transformation to aggressive GEM-PNST. Unbiased insertional mutagenesis screening suggested that these effects were mediated by STAT3 signaling. Immunohistochemistry demonstrated phosphorylated STAT3 (Tyr705) in human and mouse tumors. A specific STAT3 inhibitor blocked neurofibroma-sphere formation in vitro, and reduced neurofibroma growth in vivo; STAT3 knockdown by shRNA prevented MPNST formation in vivo. Finally, reducing EGFR activity strongly reduces pSTAT3 in vivo. Thus, an EGFR-STAT3 pathway regulates neurofibroma number and neurofibroma growth, and promotes transformation.

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号